The active substance is ipidacrine hydrochloride monohydrate (1 ml of solution contains 15 mg of ipidacrine hydrochloride monohydrate in terms of anhydrous substance).
The excipient is water for injection.
The solution for injection is administered intramuscularly or subcutaneously. The dose and duration of treatment should be determined individually, depending on the severity of the disease.
Diseases of the peripheral nervous system
Mono- and polyneuropathy of various origins: subcutaneously or intramuscularly inject 5-15 mg 1-2 times a day, the course of treatment is 10-15 days (in severe cases, up to 30 days); further treatment should be continued in the tablet form of ipidacrine.
Myasthenia and myasthenic syndrome: subcutaneously or intramuscularly inject 5-30 mg 1-3 times a day, followed by the transition to a tablet form. The general course of treatment is 1-2 months. If necessary, the treatment can be repeated several times with a break between courses of 1-2 months.
Diseases of the central nervous system
Bulbar paralysis and paresis: subcutaneously and intramuscularly 5-15 mg 1-2 times a day, the course of treatment is 10-15 days, if possible, you should switch to a tablet form.
The recovery period for organic lesions of the central nervous system
Intramuscularly 10-15 mg 1-2 times a day, the course of treatment is up to 15 days, then, if possible, 1-2 times a day.
pregnant
"Paraplexin®" increases the tone of the uterus and can cause premature birth, therefore, during pregnancy, the use of the preparation is contraindicated.
During lactation, the use of the preparation is also contraindicated.
Children
There are no systematized data on the use of the parenteral form of ipidacrine hydrochloride in children (under the age of 18 years), therefore, it should not be used in children.
Drivers
During the period of treatment, it is necessary to refrain from driving a car, as well as from engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Symptoms: bronchospasm, lacrimation, increased sweating, pupillary constriction, nystagmus, increased peristalsis of the gastrointestinal tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, lowering blood pressure, anxiety, anxiety, agitation, fear , ataxia, convulsions, coma, speech disorder, drowsiness, general weakness.
Treatment6, symptomatic therapy should be used, m-anticholinergics should be used: atropine, cyclodol, metacin and others.
From the side of the cardiovascular system: increased heart rate, decreased heart rate.
From the nervous system: when using high doses - dizziness, headache, drowsiness, general weakness, convulsions.
On the part of the respiratory system: increased separation of bronchial secretions, bronchospasm.
From the digestive system: increased salivation, nausea; when using high doses - vomiting, diarrhea, jaundice, chest pain.
From the side of the skin and subcutaneous tissues: increased sweating; allergic reactions, including rash, itching, urticaria, angioedema.
From the reproductive system: increased tone of the uterus.
In case of development of undesirable side effects, the dose should be reduced or the use of the preparation should be interrupted for a short time (for 1-2 days). Salivation and a decrease in heart rate can be reduced by m-anticholinergics (atropine and so on).
Store in the original packaging at a temperature not exceeding 25°C, out of the reach of children. Do not freeze.
Shelf life - 2 years.
There are no reviews for this product.